Tradestie Institutional Equity Comparison Engine

RXL vs UXI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RXL Overall Edge

RXL Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ProShares Ultra Health Care (RXL) driven by superior Momentum & Technical, Options & Structure. Fundamentally, RXL trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus UXI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, RXL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against UXI sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RXL N/M vs UXI N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner RXL
1Y +42.0% vs +6.8% ยท 52W Pos 89% vs 32%
Options & Structure Winner RXL
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (100th %ile IV)
RXL NYSE Arca
ProShares Ultra Health Care
Institutional Equity
$71.98
-1.1% 1D
Market Cap N/A
1M Return +12.08%
1Y Return +41.97%
Forward P/E N/M
Unified AI Score
38.5 / 100 SELL
Tech 18.0 Fund 30.0 Flow 50.0 Mom 21.1
UXI NYSE Arca
ProShares Ultra Industrials
Institutional Equity
$49.27
-3.64% 1D
Market Cap N/A
1M Return -3.45%
1Y Return +6.81%
Forward P/E N/M
Unified AI Score
38.0 / 100 SELL
Tech 26.0 Fund 52.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RXL +41.97% UXI +6.81% Spread: +31.67 pp (RXL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RXL TTM Op. Margin: N/A UXI TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RXL vs UXI. Trailing 12-month operating profitability (RXL N/A vs UXI N/A) and valuation multiples (RXL N/M vs UXI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RXL (3) vs UXI (0)
Institutional Metric RXL UXI Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 89% ($43โ€“$76) 32% ($42โ€“$65) Stronger Trend RXL
Beta / 30D Volatility Risk Regime 0.54ฮฒ ยท 41% Vol 1.92ฮฒ ยท 51% Vol Lower Realized Risk RXL
Unified Institutional Score Composite Signal 38.5 / 100 (SELL) 38.0 / 100 (SELL) Higher Composite RXL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RXL vs UXI Buy Guide
RXL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live RXL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
UXI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live UXI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RXL nor UXI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.